These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38292867)

  • 1. Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2024; 15():1365027. PubMed ID: 38292867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
    Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
    Leukemia; 2017 Oct; 31(10):2278. PubMed ID: 28751764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    Quitt O; Luo S; Meyer M; Xie Z; Golsaz-Shirazi F; Loffredo-Verde E; Festag J; Bockmann JH; Zhao L; Stadler D; Chou WM; Tedjokusumo R; Wettengel JM; Ko C; Noeßner E; Bulbuc N; Shokri F; Lüttgau S; Heikenwälder M; Bohne F; Moldenhauer G; Momburg F; Protzer U
    J Hepatol; 2021 Nov; 75(5):1058-1071. PubMed ID: 34171437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell-Based Cancer Immunotherapy.
    Chen Y; Li W; Wang Z; Yu Y; Li J; Ding Y; Hu Z; Liu Q; Yang Z; Gao J
    Adv Mater; 2024 Jan; 36(3):e2306736. PubMed ID: 37853568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
    Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
    PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
    Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
    J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.
    Fu M; He Q; Guo Z; Zhou X; Li H; Zhao L; Tang H; Zhou X; Zhu H; Shen G; He Y; Lei P
    Front Immunol; 2019; 10():1396. PubMed ID: 31293575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
    Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
    Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
    Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.
    Kakiuchi-Kiyota S; Ross T; Wallweber HA; Kiefer JR; Schutten MM; Adedeji AO; Cai H; Hendricks R; Cohen S; Myneni S; Liu L; Fullerton A; Corr N; Yu L; de Almeida Nagata D; Zhong S; Leong SR; Li J; Nakamura R; Sumiyoshi T; Li J; Ovacik AM; Zheng B; Dillon M; Spiess C; Wingert S; Rajkovic E; Ellwanger K; Reusch U; Polson AG
    Leukemia; 2022 Apr; 36(4):1006-1014. PubMed ID: 35001074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
    Stein-Merlob AF; Ganatra S; Yang EH
    Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
    Basnet S; Santos JM; Quixabeira DCA; Clubb JHA; Grönberg-Vähä-Koskela SAM; Arias V; Pakola S; Kudling TV; Heiniö C; Havunen R; Cervera-Carrascon V; Sorsa S; Anttila M; Kanerva A; Hemminki A
    Mol Ther Oncolytics; 2023 Mar; 28():59-73. PubMed ID: 36699617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.